NYSEMKT: MAIAMaia Biotechnology Inc Stock
$1.55+0.01 (+0.65%)
Updated Apr 17, 2025
MAIA Price
$1.55
Fair Value Price
N/A
Market Cap
$45.86M
52 Week Low
$1.40
52 Week High
$5.99
P/E
-1.48x
P/B
12.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.79
Operating Cash Flow
-$16M
Beta
0.49
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MAIA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MAIA
Ranked#220 of 463
Ranked#220 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important MAIA news, forecast changes, insider trades & much more!
MAIA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MAIA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MAIA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MAIA is poor value based on its book value relative to its share price (12.62x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
MAIA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MAIA due diligence checks available for Premium users.
Valuation
MAIA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.48x
Industry
-177.72x
Market
27.98x
MAIA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.62x
Industry
4.05x
MAIA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MAIA's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.6M
Profit Margin
0%
MAIA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.2M
Liabilities
$6.5M
Debt to equity
1.79
MAIA's short-term assets ($10.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MAIA's short-term assets ($10.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MAIA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
$0.0
Financing
$4.8M
MAIA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MAIA vs Biotech Stocks
Maia Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.